We’re in the year of the biotech buyout, and here are five prime targets By: MarketWatch January 23, 2017 at 05:17 AM EST One catalyst: Big drug companies are running out of ideas, writes Michael Brush. Read More >> Related Stocks: Acadia Pharmaceutica Allergan Plc Amgen Biogen Idec Biomarin Pharmaceuticals Celgene Corp Eli Lilly Gilead Sciences Incyte Corp Integra Lifesciences Johnson & Johnson Merck & Co Novartis Ag ADR Pfizer Standard & Poors 500 Tesaro Inc Teva Pharmaceutical Industries ADR Valeant Pharmaceuticals International, Inc. Vertex Pharmaceuticals